Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YM155 + erlotinib
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
YM155 + erlotinib is a combination therapy consisting of YM155, a potent selective survivin inhibitor, and erlotinib, an EGFR tyrosine kinase inhibitor. This combination was developed to overcome resistance to EGFR TKIs in EGFR mutation-positive non-small cell lung cancer (NSCLC), particularly in cases with PTEN loss. YM155 works by suppressing survivin expression, which can restore sensitivity to erlotinib-induced apoptosis in resistant cancer cells.
02
Targets
EGFR (Epidermal growth factor receptor)BIRC5 (Survivin)
Beyond the preview
Go deeper on YM155 + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YM155 + erlotinib.